Retracted: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma (Hepatology, (2011), 53, (1943-1958), 10.1002/hep.24293);Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

Hepatology

Volumn 53, Issue 6, 2011, Pages 1943-1958

  Omar, Hany A ^a,b   Chou, Chih Chien ^a   Berman Booty, Lisa D ^a   Ma, Yihui ^a   Hung, Jui Hsiang ^c   Wang, Dasheng ^a   Kogure, Takayuki ^d   Patel, Tushar ^d   Terracciano, Luigi ^e   Muthusamy, Natarajan ^f   Byrd, John C ^f   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a College of Pharmacy ^*  (United States)

^b Beni Suef University   (Egypt)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d Division of Gastroenterology   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; FINGOLIMOD; PROTEIN KINASE C DELTA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; [2 AMINO 2 [4 [(6 METHYLHEPTYL)OXY]PHENETHYL]PENTAN 1 OL];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL HOMING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; LIVER CELL CARCINOMA; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR XENOGRAFT; UPREGULATION;

EID: 79957525337     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.32736     Document Type: Erratum

References (28)

1. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 477-483.
2. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
5. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-195.
6. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 2005; 4: 1430-1438.
7. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 2008; 68: 1204-1212.
8. Martin R. Multiple sclerosis: closing in on an oral treatment. Nature 2010; 464: 360-362.
9. Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1, 3-diols and 2-aminoethanols. J Med Chem 2000; 43: 2946-2961.
10. Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, et al. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 2009; 76: 957-968.
11. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T. The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fc epsilon receptor I triggering. J Exp Med 1999; 190: 1-8.
12. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006; 70: 1534-1541.
13. Dragun D, Bohler T, Nieminen-Kelha M, Waiser J, Schneider W, Haller H, et al. FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int 2004; 65: 1076-1083.
14. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004; 279: 34643-34654.
15. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4, 387 tissue samples. Am J Clin Pathol 2008; 129: 899-906.
16. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
17. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009; 5: 428-434.
18. Yusof YA, Yan KL, Hussain SN. Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease. Anal Quant Cytol Histol 2003; 25: 332-338.
19. Reyland ME. Protein kinase Cdelta and apoptosis. Biochem Soc Trans 2007; 35: 1001-1004.
20. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-189.
21. Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, et al. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem 2010; 111: 218-228.
22. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010; 70: 5438-5447.
23. Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010; 16: 3182-3192.
24. D'Costa AM, Robinson JK, Maududi T, Chaturvedi V, Nickoloff BJ, Denning MF. The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas. Oncogene 2006; 25: 378-386.
25. Varga A, Czifra G, Tallai B, Nemeth T, Kovacs I, Kovacs L, et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol 2004; 46: 462-465.
26. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR, Bradford AP. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol 2008; 39: 21-29.
27. Jackson DN, Foster DA. The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J 2004; 18: 627-636.
28. Tchou JC, Lin X, Freije D, Isaacs WB, Brooks JD, Rashid A, et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 2000; 16: 663-676.